with no breakthrough hpv infections due to waning immunity, the minimum protective anti hpv antibody level could not be ascertained. nevertheless antibody titer has been used as a surrogate marker of protection in clinical trials, particularly in adolescent populations in whom efficacy studies are not feasible.